CHLOROPTIC S.O.P.
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHLOROPTIC S.O.P. (CHLOROPTIC S.O.P.).
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
| Metabolism | Primarily hepatic via glucuronidation; minor metabolism by reduction to aryl amines. |
| Excretion | Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%) |
| Half-life | Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections |
| Protein binding | 15-20% bound to plasma proteins (albumin) |
| Volume of Distribution | 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid |
| Bioavailability | Topical ophthalmic: low systemic absorption (<5%); oral: 30-50% |
| Onset of Action | Topical ophthalmic: 30 minutes to 1 hour |
| Duration of Action | Topical ophthalmic: 4-6 hours; sustained release formulation provides coverage for up to 12 hours |
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established; use only if potential benefit outweighs risk. |
| Geriatric use | Use with caution in elderly patients due to increased risk of adverse effects; monitor intraocular pressure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHLOROPTIC S.O.P. (CHLOROPTIC S.O.P.).
| Breastfeeding | Chloramphenicol is excreted into breast milk. M/P ratio unknown. Potential for bone marrow suppression and gray baby syndrome in nursing infants. Contraindicated during breastfeeding. |
| Teratogenic Risk | Chloroptic S.O.P. contains chloramphenicol, which crosses the placenta. First trimester: minimal data, but theoretical risk of gray baby syndrome. Second and third trimesters: associated with gray baby syndrome in neonates if administered near term due to immature hepatic glucuronidation; avoid use in pregnancy unless no alternative. |
■ FDA Black Box Warning
Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) have been reported after topical ophthalmic use.
| Serious Effects |
Hypersensitivity to chloramphenicol or any component; concurrent use with drugs that suppress bone marrow; history of drug-induced blood dyscrasias.
| Precautions | Bone marrow suppression including aplastic anemia; avoid prolonged use; monitor blood counts if used systemically; risk of superinfection; not for viral or fungal infections. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal complete blood count (CBC) weekly due to risk of aplastic anemia. Fetal monitoring not typically required unless maternal systemic toxicity occurs. Assess neonatal CBC and bilirubin if maternal use near delivery. |
| Fertility Effects | No known effects on fertility based on available data. Animal studies not reported for ophthalmic formulation. |